Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -29.2% | +68.7% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -29.2% over three years. Forward estimates point to Revenue at +68.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
C4 Therapeutics, Inc. NASDAQ:CCCC | $335.86M | $4.06 | Not rated | -4.9 | -1.00% |
OmniAb, Inc. NASDAQ:OABI | $264.31M | $2.22 | Not rated | -5.2 | +207.88% |
Armata Pharmaceuticals, Inc. AMEX:ARMP | $254.77M | $6.94 | Not rated | -0.9 | -56.58% |
Codexis, Inc. NASDAQ:CDXS | $233.15M | $2.57 | Not rated | -7.1 | -29.01% |
Innate Pharma S.A. NASDAQ:IPHA | $171.37M | $1.83 | Not rated | -3.0 | -42.46% |
Molecular Partners AG NASDAQ:MOLN | $147.61M | $3.94 | Not rated | -2.0 | -36.40% |
Insight Molecular Diagnostics Inc. NASDAQ:IMDX | $144.94M | $5.40 | Not rated | -3.9 | -73.50% |
Invivyd, Inc. NASDAQ:IVVD | $126.86M | $0.96 | Not rated | -3.9 | -81.18% |
Milestone Pharmaceuticals Inc. NASDAQ:MIST | $113.80M | $1.33 | Not rated | -2.5 | -80.24% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $50.69M | $0.78 | Not rated | -4.6 | -54.34% |
Continue the stock analysis
Jump to another research area for this company.